Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19

Launched by UNIVERSITY OF CALGARY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a supplement called creatine monohydrate might help people who are suffering from fatigue due to Long COVID. Many individuals with Long COVID feel unusually tired after doing physical or mental activities, a condition known as post-exertional malaise (PEM). The goal of the study is to see if taking creatine can improve this fatigue and help people feel better.

To participate in this trial, you need to be between 18 and 74 years old and have been experiencing symptoms of Long COVID for at least three months after a confirmed COVID-19 diagnosis. You should also be dealing with post-exertional malaise as measured by a specific questionnaire. However, if you have an allergy to creatine, have taken it in the last eight weeks, have a recent injury that affects your ability to exercise, or have changed your medications for Long COVID in the past month, you won’t be eligible. If you join, you can expect to learn more about how creatine might help, and you will be contributing to important research that could benefit others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Experiencing symptoms at least 3 months after a COVID-19 diagnosis confirmed by positive polymerase chain reaction (PCR) test
• • Experiencing post-exertional malaise, as per the DePaul Symptom Questionnaire
• Exclusion Criteria:
• • Allergy or intolerance to creatine monohydrate or maltodextrin
• • Supplemented with creatine in the past eight weeks
• • orthopaedic injury or condition that would prevent exercise testing
• • change in medication related to Long COVID symptom management in the past month.